DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study

Location: Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Purpose:

The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.

Sponsor: Delfi Diagnostics Inc.

https://clinicaltrials.gov/ct2/show/NCT04825834

Eligibility:

• Age ≥ 50 years
• Current or Former Smoker, ≥ 20 pack-years (pack years = number of packs per day X number of years smoked)
• With or without lung cancer OR with other invasive cancer prior to treatment or surgery
• No hematologic malignancies or myelodysplasia
• No history of organ tissue transplantation
• No history of blood product transfusion
• Not currently pregnant

Time Commitment: Approx. 1 year